I want to add some important nuance here that often gets lost in the "it's the same molecule" argument.
Yes, the API is semaglutide in both cases. But pharmaceutical formulation matters enormously. The stability of the peptide in solution, the pH of the buffer, the preservatives used, the sterility assurance level — these all impact safety and efficacy.
The FDA has issued multiple warnings about compounded semaglutide products, including reports of adverse events linked to products from compounding pharmacies that were not properly formulated.[1]
That doesn't mean all compounded sema is bad. It means the variance is much higher. With Wegovy, you know exactly what you're getting every single time. With compounded, you're trusting the compounding pharmacy's quality systems.
Key questions to ask your compounder:
- Are you a 503A or 503B facility? (503B has more FDA oversight)
- Do you provide certificates of analysis for each batch?
- What is the source of your semaglutide API?
- What are the beyond-use dates on your product?
- Has your facility had any FDA warning letters? (These are public record)
[1] U.S. Food and Drug Administration. "Compounded Semaglutide Products." Safety Communication, 2023.
Last edited: Aug 17, 2025 at 12:43 AM